Effect of new antitumor compounds based on azoloazine derivatives on the level of DNA damage in normal Vero cells in the DNA comet test
https://doi.org/10.18699/SSMJ20230614
Abstract
The aim of the work is to study the effect of new azoloazine derivatives on the level of DNA damage to Vero cells (DNA comet test) in vitro by alkaline gel electrophoresis.
Material and methods. The objects of the study are 8-(piperidinocarbonyl)3-cyclohexylimidazo[5,1-d][1,2,3,5]tetrazine-4(3H)-one (1), diethyl ether 4-aminoimidazo[5,1-c][1,2,4]triazine3,8-dicarboxylic acid (2), 4-amino-8-ethoxycarbonylimidazo[5,1-c][1,2,4]triazine-3-N-(p-toluyl)carboxamide (3). Epirubicin was chosen as a comparison drug. The compounds were used in doses of 1/2, 1/10 and 1/50 IC50. The Vero cell line cultured according to the standard protocol was selected as the cell model. To assess genotoxicity, an alkaline version of the DNA comet method was used, which has a high sensitivity and allows detecting DNA damage.
Results. Analysis of the data obtained indicates that the tested compounds 1-3 enhance DNA damage in non-tumor cells. Compound 1 has the most pronounced genotoxic effect. Thus, the use of this substance in a dose of ½ IC50 led to a significant increase in the length of the comet’s tail by 1.5 times. It was noted that DNA damage under the action of compound 1 in the studied doses and of epirubicin was on the same level.
Conclusions. The results obtained prove that compounds 1-3 may have a potentially carcinogenic effect. However, this assumption requires further in-depth experimental studies.
About the Authors
A. H. Al-Humairi
Volgograd State Medical University of Minzdrav of Russia; Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg of Tomsk National Research Medical Center of RAS
Russian Federation
Russian Federation
Ahmed H. Al-Humairi - PhD in Pharmacology, Clinical Pharmacology, and Oncology, Radiation Therapy.
400131, Volgograd, Pavshikh Bortsov ave., 1; 634028, Tomsk, Lenina ave., 3
D. L. Speranskiy
Volgograd State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Dmitry L. Speransky - doctor of medical sciences, professor.
400131, Volgograd, Pavshikh Bortsov ave., 1
M. Yu. Minakova
Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg of Tomsk National Research Medical Center of RAS
Russian Federation
Russian Federation
Maria Yu. Minakova - doctor of medical sciences.
634028, Tomsk, Lenina ave., 3
N. V. Cherdyntseva
Research Institute of Oncology of Tomsk National Research Medical Center of RAS
Russian Federation
Russian Federation
Nadezhda V. Cherdyntseva - doctor of biology sciences, professor, corresponding member of RAS.
634009, Tomsk, Kooperativny ln., 5
V. V. Udut
Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg of Tomsk National Research Medical Center of RAS
Russian Federation
Russian Federation
Vladimir V. Udut - doctor of medical sciences, professor, corresponding member of RAS.
634028, Tomsk, Lenina ave., 3
References
1. Guidelines for the chemotherapy of neoplastic diseases. Eds. N.I. Perevodchikova, V.A. Gorbunova. Moscow: Practical medicine, 2005. 704 p. [In Russian].
2. Chu E, de Vita V. Jr. Cancer chemotherapy. Moscow: Practice, 2009. 455 p. [In Russian].
3. Juarez-Moreno K., Gonzalez E.B., GirónVazquez N., Chávez-Santoscoy R.A., Mota-Morales J.D., Perez-Mozqueda L.L., Garcia-Garcia M.R., Pestryakov A., Bogdanchikova N. Comparison of cytotoxicity and genotoxicity effects of silver nanoparticles on human cervix and breast cancer cell lines. Hum. Exp. Toxicol. 2017;36(9):931–948. doi: 10.1177/0960327116675206
4. Sinaiko V.V., Artemova N.A., Yurkshtovich T.L., Bychkovsky P.M., Frolenkov K.A. Comparative efficacy of temobel and temodal drugs in multimodality treatment of high-grade (III–IV). Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy. 2015;14(2):59–64. [In Russian]. doi: 10.17650/17269784-2015-14-2-59-64
5. Abdel-Rahman O., Fouad M. Temozolomidebased combination for advanced neuroendocrine neoplasms: A systematic review of the literature. Future Oncol. 2015;8(11):1275–1290. doi: 10.2217/fon.14.302
6. Sadchikova E.V., Mokrushin V.S. Interaction of 3,8-disubstituted imidazo[5,1-c][1,2,4]triazines with nucleophiles. Khimiya geterotsiklicheskikh soedineniy = Chemistry of Heterocyclic Compounds. 2014;50(7):1014–1020. doi: 10.1007/s10593-0141557-5
7. Sadchikova E.V. Synthesis of new azolo[5,1-d] [1,2,3,5]tetrazin-4-ones – analogs of antitumor agent temozolomide. Russ. Chem. Bull. 2016; 65(7): 1867– 1872. doi: 10.1007/s11172-016-1522-9
8. Konenkov V.I., Rachkovskaya L.N., Letyagin A.Yu., Borovskaya T.G., Shurlygina A.V., Robinson M.V., Korolev M.A., Kotlyarova A.A., Popova T.V., Rachkovsky E.E., Vychuzhanina A.V., Mashanova V.A. Study of the DNA-damage by new normothymic medicinal on the basis of the complex of lithium citrate, polymethylsyloxane and aluminum oxide by DNA comet assay in vivo. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2018;38(4):5–10. [In Russian]. doi: 10.15372/SSMJ20180401
9. Tyukavin A.I., Suchkov S.V. Tumor growth – a modern view of pathogenesis and pharmacotherapy (lecture). Formuly farmatsii = Pharmacy Formulas. 2021;3(2):86–96. [In Russian]. doi: 10.17816/phf65284
10. Al-Humairi A.H., Speransky D.L., Sadchikova E.V. Synthesis and cytotoxic activity on cell cultures of new azolotriazines. Khimiko-farmatsevticheskiy zhurnal = Pharmaceutical Chemistry Journal. 2022;56(6):742–747 [In Russian]. doi: 10.1007/s11094022-02704-0
11. Gaidai E.A., Dorofeeva A.A., Kryshen K.L., Gaidai D.S. Methodological aspects of DNA comet assay in vivo in preclinical research. Laboratornyye zhivotnyye dlya nauchnykh issledovaniy = Laboratory Animals for Science. 2020;(3):16–24. [In Russian]. doi: 10.29296/2618723X-2020-03-03
12. Andreani N.A., Renzi S., Piovani G., Marsan P.A., Bomba L., Villa R., Ferrari M., Dotti S. Potential neoplastic evolution of Vero cells: in vivo and in vitro characterization. Cytotechnology. 2017;69(5):741–750. doi: 10.1007/s10616-017-0082-7
13. Al-Humairi A.H., Ostrovsky O.V., Zykova E.V., Speransky D.L., Alekseeva D.L., Sadchikova E.V. Cytotoxic activity of azolotriazine derivatives in the study of MCF human breast cancer cells. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta = Journal of the Volgograd State Medical University. 2022;19(1):133–141. [In Russian]. doi: 10.19163/19949480-2022-19-1-133-141
14. Evaluation of genotoxic properties by in vitro DNA comet method. Methodological recommendations MR 4.2.0014-10. Moscow: Federal Center for Hygiene and Epidemiology of Rospotrebnadzor, 2011, 16 p. [In Russian].
15. Guidelines for conducting preclinical studies of drugs. Moscow: Grif i K, 2013, 944 p.
16. Savateev K.V., Ulomsky E.N., Butorin I.I., Charushin V.N., Rusinov V.L., Chupakhin O.N. Azoloazines as A2α-receptor antagonists. Structure and properties. Uspekhi khimii = Russian Chemical Reviews. 2018; 87(7):636–669. [In Russian]. doi: 10.1070/RCR4792
17. Garza-Morales R., Gonzalez-Ramos R., Chiba A., Montes de Oca-Luna R., McNally L.R., McMasters K.M., Gomez-Gutierrez J.G. Temozolomide enhances triple-negative breast cancer virotherapy in vitro. Cancers (Basel). 2018;10(5): e144. doi: 10.3390/cancers10050144
18. Al-Humairi A.H., Speransky D.L., Rybalkina O.Yu., Sadchikova E.V., Buldakov M.A., Frolova A.A., Cherdyntseva N.V., Udut V.V. Genotoxic effects of new azoloazine derivatives with antitumor activity in mcf-7 tumor cell culture. Khimiko-farmatsevticheskiy zhurnal = Pharmaceutical Chemistry Journal. 2023;57(6):24–29. [In Russian]. doi: 10.30906/00231134-2023-57-6-24-29
19. Svirnovsky A.I. Resistance of tumor cells to therapeutic effects as a biomedical problem. Meditsinskie novosti = Medical News. 2011;9:30–38. [In Russian].
20. Ramis G., Thomàs-Moyà E., de Mattos S.F., Rodríguez J., Villalonga P. EGFR inhibition in glioma cells modulates rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. PLoS One. 2012;7(6):e38770. doi: 10.1371/journal.pone.0038770
21. Tatar Z., Thivat E., Planchat E., Gimberques P., Gadea E., Abrial C., Durando X. Temozolomide and unusual indications: Review of literature. Cancer Treat. Rev. 2013;39(2):125–135. doi: 10.1016/j.ctrv.2012.06.002
Review
Views:
373
Email this article 